股东批准了Recursion和Exscientia之间的合并, Shareholders approve merger between Recursion and Exscientia, set to close by Nov. 20, 2024.

Recurtion和Excientia的股东已经批准了他们提议的合并,预计最后条件尚未确定,将于2024年11月20日结束。 Shareholders of Recursion and Exscientia have approved their proposed merger, expected to close on November 20, 2024, pending final conditions. Recursion 将在当天上午 7：30 主持一次更新电话会议。 Recursion will host an update call that day at 7:30 a.m. ET,在他们的社交媒体频道上进行现场直播。 ET, live-streamed on their social media channels. 合并的目的是将Recursion的测绘能力与Exsocitia的分子设计结合起来,以便更快地发现药物。 The merger aims to combine Recursion's mapping capabilities with Exscientia's molecular design for faster drug discovery. 股东可在通话前或通话期间提出问题。 Shareholders can submit questions ahead of or during the call.